84 related articles for article (PubMed ID: 21479900)
1. Genetics and molecular biology of mesothelioma.
Fennell DA
Recent Results Cancer Res; 2011; 189():149-67. PubMed ID: 21479900
[No Abstract] [Full Text] [Related]
2. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
[TBL] [Abstract][Full Text] [Related]
3. [Genetic analysis of brain tumors].
Tabuchi K; Shiraishi T
Nihon Rinsho; 2005 Sep; 63 Suppl 9():35-43. PubMed ID: 16201497
[No Abstract] [Full Text] [Related]
4. Simultaneous silencing of XIAP and survivin causes partial mesenchymal-epithelial transition of human pancreatic cancer cells via the PTEN/PI3K/Akt pathway.
Yi XP; Han T; Li YX; Long XY; Li WZ
Mol Med Rep; 2015 Jul; 12(1):601-8. PubMed ID: 25707849
[TBL] [Abstract][Full Text] [Related]
5. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
6. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR.
Maiese K
Indian J Med Res; 2013 Feb; 137(2):243-6. PubMed ID: 23563366
[No Abstract] [Full Text] [Related]
11. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
12. Understanding the Villain: DMBA-induced preantral ovotoxicity involves selective follicular destruction and primordial follicle activation through PI3K/Akt and mTOR signaling.
Sobinoff AP; Mahony M; Nixon B; Roman SD; McLaughlin EA
Toxicol Sci; 2011 Oct; 123(2):563-75. PubMed ID: 21785161
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways: P-Rex in cancer.
Pandiella A; Montero JC
Clin Cancer Res; 2013 Sep; 19(17):4564-9. PubMed ID: 23753921
[TBL] [Abstract][Full Text] [Related]
14. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
15. PTEN: life as a tumor suppressor.
Simpson L; Parsons R
Exp Cell Res; 2001 Mar; 264(1):29-41. PubMed ID: 11237521
[TBL] [Abstract][Full Text] [Related]
16. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.
Altomare DA; You H; Xiao GH; Ramos-Nino ME; Skele KL; De Rienzo A; Jhanwar SC; Mossman BT; Kane AB; Testa JR
Oncogene; 2005 Sep; 24(40):6080-9. PubMed ID: 15897870
[TBL] [Abstract][Full Text] [Related]
17. PLC and PI3K/Akt/mTOR signalling in disease and cancer.
Follo MY; Manzoli L; Poli A; McCubrey JA; Cocco L
Adv Biol Regul; 2015 Jan; 57():10-6. PubMed ID: 25482988
[TBL] [Abstract][Full Text] [Related]
18. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
20. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
